|
|
|
|
|
|
|
|
|
Orphans and Incentives: Developing Technologies to Address Emerging Infections
|
|
Released On:
|
January 01, 1997 |
|
|
|
|
Read and Purchase
|
|
|
The first workshop, held in February 1997, set out to learn what has been done and what is needed for the public and private sectors to collaborate effectively and productively for the public's health. Emphasis was on cooperation in those product areas where returns from the market were too small or too complicated by other factors to compete in industry portfolios with other demands for investment. Quintessential examples of such products are vaccines, and in some instances, therapies for the diseases of children, for malaria, and for HIV/AIDS. Each of these offers lessons that can be applied to deal systematically with emerging infectious diseases.
In learning these lessons, the workshop recognized that while there are differences between the public health requirements of developing countries and industrialized countries, the growth of the middle class in the former and the vulnerability of the latter to diseases once thought to reside permanently 'offshore' are doing much to narrow those differences.
The workshop studied these issues in more detail through a primary case study of the Children's Vaccine Initiative (CVI), formally established in 1991 as the first comprehensive effort to yoke public- and private-sector scientific advances to a global public health priority through purposive intersectoral collaboration. The workshop integrated the lessons learned from the CVI with other experiences from disease-focused efforts, notably malaria and HIV/AIDS.
The purpose of the first workshop report was to combine the CVI experiences and the tasks the lessons suggest as points of reference for further action. The report focused on the issue of those constraints that have left undefined groups of 'urgently needed medical products in an orphaned condition which demands special attention.' The lessons learned fall into four sets of messages concerning: what makes intersectoral collaboration genuine, the notion of the product 'life cycle,' the implications of divergent sectoral mandates and notions of risk, and the roles of advocacy and public education.
These lessons, taken together, signal needs for: (1) more information, (2) more predictability, and (3) more sharing of costs and risks, if the requirements for products for emerging infectious diseases are to be satisfied. Looked at systematically across the product cycle, these sort into more specific categories where incentives might be developed to bolster the competitiveness of such public health products in industrial portfolios.
The report lays out these categories, highlighting actions expected to be especially critical for advancing the infectious disease enterprise as a whole.
|
|
Related Reports
|
|
|
|
Vector-Borne Diseases: Understanding the Environmental, Human Health, and Ecological Connections. Workshop Summary
Mar 18, 2008
|
|
|
|
Global Infectious Disease Surveillance and Detection: Assessing the Challenges. Workshop Summary
Oct 22, 2007
|
|
|
|
Ethical and Legal Considerations in Mitigating Pandemic Disease. Workshop Summary
Jun 11, 2007
|
|
|
|
Addressing Foodborne Threats to Health: Policies, Practices, and Global Coordination. Workshop Summary
Sep 15, 2006
|
|
|
|
Ending the War Metaphor: The Changing Agenda for Unraveling the Host-Microbe Relationship. Workshop Summary
Jun 23, 2006
|
|
|
|
The Impact of Globalization on Infectious Disease Emergence and Control: Exploring the Consequences and Opportunities. Workshop Summary
Mar 3, 2006
|
|
|
|
Ensuring an Infectious Disease Workforce: Education and Training Needs for the 21st Century - Workshop Summary
Feb 24, 2006
|
|
|
|
The Threat of Pandemic Influenza: Are We Ready? A Workshop Summary
Nov 16, 2004
|
|
|
|
The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects. Workshop Summary
Jun 15, 2004
|
|
|
|
Learning from SARS: Preparing for the Next Disease Outbreak. Workshop Summary
Jan 27, 2004
|
|
|
|
The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment- Workshop Summary
Apr 10, 2003
|
|
|
|
Considerations for Viral Disease Eradication: Lessons Learned and Future Strategies
Jul 19, 2002
|
|
|
|
The Emergence of Zoonotic Diseases: Understanding the Impact on Animal and Human Health - Workshop Summary
Apr 16, 2002
|
|
|
|
Biological Threats and Terrorism: Assessing the Science and Response Capabilities
Jan 29, 2002
|
|
|
|
Emerging Infectious Diseases from the Global to the Local Perspective: Workshop Summary
Apr 3, 2001
|
|
|
|
Managed Care Systems and Emerging Infections: Opportunities for Strengthening Surveillance, Research, and Prevention
Jan 1, 2000
|
|
|
|
Public Health Systems and Emerging Infections: Assessing the Capabilities of the Public and Private Sectors
Jan 1, 2000
|
|
|
|
Antimicrobial Resistance: Issues and Options
Jan 1, 1998
|
|
|
|
Emerging Infections: Microbial Threats to Health in the United States
Jan 1, 1992
|
|
|
|
|
|
|
Last Updated: 1/13/2003, 11:16 AM
|
|
|
|
|
|
|
|